Their big idea is deceptively simple: take fragile, high-maintenance pluripotent stem cells, stick them in tiny alginate capsules, and gently swirl them in bioreactors. Voilà—massive expansion, better viability, and allegedly fewer angry cell deaths. It is like giving stem cells a spa day while tricking them into working overtime.

From a scientific standpoint, it is elegant. From an industrial one, it is a clever play on scalability—a word everyone in cell therapy likes to say, but few can make actually happen. TreeFrog thinks they can. And honestly, maybe they can. They are funded, fast-moving, and French, which never hurts in biotech PR.

Scientifically, the pitch is strong: reduced reagent use, improved reproducibility, and high sensitivity from minimal input material—ideal for clinical or rare samples.

Scientifically, it’s smart: you’re harnessing real space effects—altered gene expression, crystal growth, immune phenotypes—with no astronaut or manual intervention.

Pherecydes Pharma (now known as Phaxiam Therapeutics) pioneers precision phage therapy to tackle antibiotic-resistant bacterial infections. Their innovation centers on rapid matching of custom bacteriophage cocktails to a patient’s specific pathogen (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, E. coli) using high-throughput screening and GMP production. The platform has delivered promising compassionate-use results in bone, joint, burn, and bloodstream infections, and has entered Phase II trials (e.g., PhagoDAIR) for prosthetic joint infections. Production-ready since 2021, their phage library and manufacturing capabilities support modular, strain-specific treatments—offering a targeted, adaptive alternative to broad-spectrum antibiotics without relying on synthetic analogues.

In addition to its therapeutic compound, Seekyo integrates diagnostic and theranostic tools, including companion diagnostics and breath-based VOC markers, to stratify patients and monitor treatment response. The company is in a preclinical stage with validated safety and efficacy in both small and large animal models and is preparing for first-in-human trials. Based in Futuroscope, France, Seekyo is part of the Paris-Saclay Cancer Cluster and aims to position itself as a pioneer in precision oncology through localized activation and patient-tailored treatment.

Their research focuses on therapeutic applications for human and animal health, as well as biocontrol solutions in the food and environmental sectors. By combining molecular biology, phage genomics, and formulation technologies, Greenphage develops safe and highly targeted products designed to preserve the beneficial microbiota while eliminating pathogenic strains. The company’s platform is aligned with the global “One Health” strategy, addressing the growing public health threat of antimicrobial resistance.

specializing in bacteriophage-derived technologies to fight antimicrobial resistance in animal health.

Based near Lyon, it studies and engineers phages and their proteins, such as endolysins,

to develop targeted antibacterial therapies and diagnostic tools.

Its LabMastis S.A kit detects Staphylococcus aureus in dairy cattle using phage-based recognition.

Through molecular biology and protein engineering, Vetophage designs precise, eco-friendly alternatives to antibiotics,

applying the “One Health” approach to link animal, human, and environmental health.

STH Biotech is a French biotechnology company based in Évry-Courcouronnes that develops a proprietary platform called SATIVITRO® to produce rare plant-derived bioactive compounds using engineered hairy root cultures. The technology induces root systems from plant tissues, such as hemp, and grows them in controlled bioreactors to generate high yields of secondary metabolites like triterpenes and alkaloids.

By combining plant biotechnology, metabolic engineering, and bioprocess optimization, STH Biotech provides a sustainable alternative to conventional plant extraction. Its process eliminates the need for soil or light, reduces water and land use, and ensures standardized, traceable production of natural ingredients for cosmetic and health applications.

using solid‑state fermentation of fungi on agricultural by‑products to create 100% natural aromatic and functional ingredients.

Keywords: circular food system, fungal fermentation, natural flavours

applying a proprietary ultra‑high‑throughput microfluidics platform to engineer novel enzymes for sustainable production across pharma, food and chemicals.

developing a patented nanomedicine combining chemotherapy and gold nanoparticles to enhance radiotherapy for solid tumours such as glioblastoma.

developing cell-based assays and analytical tools to evaluate the safety and efficacy of biopharmaceutical products.

Keywords:

pioneering stem cell–based therapies for veterinary regenerative medicine, with standardized GMP production of mesenchymal stem cells.

developing innovative veterinary drugs and biologicals derived from recombinant proteins and peptides to improve animal health.